Daesung Microbiological Labs. Co. Ltd
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in U… Read more
Daesung Microbiological Labs. Co. Ltd (036480) - Total Liabilities
Latest total liabilities as of September 2025: ₩22.65 Billion KRW
Based on the latest financial reports, Daesung Microbiological Labs. Co. Ltd (036480) has total liabilities worth ₩22.65 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Daesung Microbiological Labs. Co. Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Daesung Microbiological Labs. Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Daesung Microbiological Labs. Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Daesung Microbiological Labs. Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
InfoBank Corporation
KQ:039290
|
Korea | ₩28.87 Billion |
|
Bahema Educação S.A
SA:BAHI3
|
Brazil | R$454.34 Million |
|
Turpaz Industries Ltd
TA:TRPZ
|
Israel | ILA347.32 Million |
|
Laser Photonics Corporation Common Stock
NASDAQ:LASE
|
USA | $13.36 Million |
|
Microlink Solutions Bhd
KLSE:0126
|
Malaysia | RM137.74 Million |
|
Bak Ambalaj Sanayi ve Ticaret AS
IS:BAKAB
|
Turkey | TL2.10 Billion |
|
edding AG
F:EDD3
|
Germany | €50.30 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Daesung Microbiological Labs. Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daesung Microbiological Labs. Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daesung Microbiological Labs. Co. Ltd (2012–2024)
The table below shows the annual total liabilities of Daesung Microbiological Labs. Co. Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩23.23 Billion | -13.78% |
| 2023-12-31 | ₩26.94 Billion | +2.55% |
| 2022-12-31 | ₩26.27 Billion | +2.56% |
| 2021-12-31 | ₩25.62 Billion | -1.29% |
| 2020-12-31 | ₩25.95 Billion | +65.55% |
| 2019-12-31 | ₩15.68 Billion | +208.03% |
| 2018-12-31 | ₩5.09 Billion | +13.45% |
| 2017-12-31 | ₩4.49 Billion | -31.99% |
| 2016-12-31 | ₩6.60 Billion | -9.96% |
| 2015-12-31 | ₩7.33 Billion | +10.10% |
| 2014-12-31 | ₩6.65 Billion | -27.91% |
| 2013-12-31 | ₩9.23 Billion | +60.20% |
| 2012-12-31 | ₩5.76 Billion | -- |